Cisplatin remains a valid option in muscle-invasive or metastatic urothelial carcinoma, and is even more efficient when nivolumab is added. The well-known side-effect profile and the limited number of treatment cycles represent great advantages over modern drug combinations such as enfortumab-vedotin plus pembrolizumab.
European urology focus. 2024 Apr 05 [Epub ahead of print]
Ursula M Vogl, Irene Testi, Maria De Santis
Oncology Institute of Southern Switzerland EOC, Bellinzona, Switzerland. Electronic address: ., Oncology Institute of Southern Switzerland EOC, Bellinzona, Switzerland; Medical Oncology Unit, University Hospital Parma, Parma, Italy., Department of Urology, Charité Universitätsmedizin, Berlin, Germany; Department of Urology, Medical University Vienna, Austria.